Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity.
John R PowerCharles DolladilleAdriel ProcureurStephane R EderhyNicolas L PalaskasLorenz H LehmannJennifer CautelaPierre-Yves CourandSalim S HayekHan ZhuVlad G ZahaRichard K ChengJoachim AlexandreFrancois RoubilleLauren A BaldassarreAlan H BaikMichal Laufer-PerlYuichi TamuraAarti AsnaniSanjeev FrancisElizabeth M GaughanPeter P RainerGuillaume BaillyDanette FlintDimitri ArangalageEve CariouRoberta FloridoAnna NarezkinaYan LiuShahneen SandhuDarryl LeongNahema IssaNicolas PiriouLucie HeinzerlingGiovanni PerettoShanthini M CruszNausheen AkhterJoshua E LevensonIsik TurkerAssie EslamiCharlotte FeniouxPedro MolinerMichel ObeidWei-Ting ChangStephen M EwerSeyed Ebrahim Kassaiannull nullDouglas B JohnsonAnju NohriaOsnat Itzhaki Ben ZadokJavid J MoslehiJoe-Elie SalemPublished in: medRxiv : the preprint server for health sciences (2024)
ICI-myocarditis can manifest with high morbidity and mortality. Myocarditis severity is associated with magnitude of troponin, thymoma, low-QRS voltage, depressed LVEF, and cardio-muscular symptoms. A risk-score incorporating these features performed well.